SABIC (2010) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
5 Mar, 2026Executive summary
Revenue reached $31.07Bn (SAR 116.53Bn) in 2025, with 3% higher sales volumes despite a 4% decline in prices; revenue declined 1% year-over-year due to lower average selling prices.
Adjusted EBITDA was $4.77Bn (SAR 17.88Bn), down 15% from 2024, with a margin of 15.3%.
Adjusted net income was $552Mn (SAR 2.07Bn), while reported net income was a loss of $6.9Bn (SAR -25.78Bn) due to special items and portfolio restructuring.
Announced $2.4Bn (SAR 9.0Bn) in dividends for 2025, reinforcing a strong commitment to shareholder returns.
Major portfolio optimization actions included divestment agreements for European Petrochemicals and ETP businesses in the Americas and Europe.
Financial highlights
Adjusted EBITDA fell 15% to $4.77Bn (SAR 17.88Bn); reported EBITDA was $4.38Bn.
Free cash flow increased 17% to $1.92Bn (SAR 7.2Bn), driven by optimized working capital and reduced CAPEX.
Net debt stood at -$0.96Bn, and net cash position increased to SAR 3.6Bn.
EBITDA margin was 14.1%; adjusted EBITDA margin fell to 15.3% from 17.8% in 2024.
Total cash generation, including portfolio optimization proceeds, reached SAR 13.99Bn.
Outlook and guidance
2026 global GDP growth projected at 2.9%.
Focus remains on operational excellence, portfolio optimization, transformation, and selective growth.
Capital investment planned at $3.5–4Bn for 2026.
Latest events from SABIC
- Q3 2024 revenue up 3% to $9.83B, stable EBITDA, and key divestments amid market headwinds.2010
Q3 202413 Mar 2026 - Q2 2024 delivered strong profit growth, portfolio optimization, and top-tier sustainability progress.2010
Q2 20242 Feb 2026 - EBITDA rose 2% to $5.2B as net income rebounded and dividends reached $2.72B.2010
Q4 20247 Jan 2026 - Q1 2025 saw stable revenue, narrowed losses, improved EBITDA, and ongoing transformation efforts.2010
Q1 202525 Dec 2025 - Adjusted EBITDA jumped 40% in Q2 2025, but net loss was $1.1B from major impairments.2010
Q2 202523 Nov 2025 - Revenue dipped but EBITDA and free cash flow were resilient as transformation gains continued.2010
Q3 20253 Nov 2025